Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Vaxcyte Inc (PCVX)

Vaxcyte Inc (PCVX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,597,207
  • Shares Outstanding, K 79,321
  • Annual Sales, $ 0 K
  • Annual Income, $ -100,080 K
  • 60-Month Beta 1.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.32
Trade PCVX with:

Options Overview Details

View History
  • Implied Volatility 58.82% ( -2.28%)
  • Historical Volatility 43.76%
  • IV Percentile 12%
  • IV Rank 17.77%
  • IV High 204.67% on 10/21/22
  • IV Low 27.29% on 06/27/22
  • Put/Call Vol Ratio 1.60
  • Today's Volume 13
  • Volume Avg (30-Day) 132
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 2,908
  • Open Int (30-Day) 7,929

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.84
  • Number of Estimates 3
  • High Estimate -0.81
  • Low Estimate -0.88
  • Prior Year -0.54
  • Growth Rate Est. (year over year) -55.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.51 +9.70%
on 01/11/23
49.31 -9.88%
on 01/03/23
-3.51 (-7.32%)
since 12/30/22
3-Month
40.10 +10.82%
on 11/17/22
49.31 -9.88%
on 01/03/23
-0.56 (-1.24%)
since 11/01/22
52-Week
17.44 +154.82%
on 06/16/22
49.31 -9.88%
on 01/03/23
+25.21 (+131.10%)
since 02/01/22

Most Recent Stories

More News
Why Investors Are Suddenly Excited About Vaxcyte

Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet.

PCVX : 44.44 (-2.01%)
PFE : 43.97 (-0.43%)
MRNA : 174.30 (-1.00%)
STRO : 7.33 (+1.24%)
MRK : 106.98 (-0.40%)
Why Shares of Vaxcyte Rose 110.7% This Week

The company released early data for a promising pneumonia vaccine.

PFE : 43.97 (-0.43%)
PCVX : 44.44 (-2.01%)
Recent Price Trend in Vaxcyte, Inc. (PCVX) is Your Friend, Here's Why

Vaxcyte, Inc. (PCVX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through...

PCVX : 44.44 (-2.01%)
Vaxcyte, Myovant rise; Dorman, Shift4 Payments fall

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Monday:

DORM : 99.12 (+2.12%)
TSLA : 181.41 (+4.73%)
MYOV : 26.89 (+0.04%)
PCVX : 44.44 (-2.01%)
SCHL : 45.03 (+1.79%)
FOUR : 65.42 (+2.15%)
Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

Incyte (NASDAQ:INCY) today announced that the Company has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development...

INCY : 85.60 (+0.54%)
MOLN : 6.48 (+0.53%)
PCVX : 44.44 (-2.01%)
AURA : 10.30 (-1.06%)
CNTA : 3.85 (-3.75%)
Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update

-- Completed Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in...

PCVX : 44.44 (-2.01%)
Vaxcyte (PCVX) Completes Enrollment in Pneumococcal Disease Study

Vaxcyte (PCVX) enrolls the last patient in the phase II portion of phase I/HH study, evaluating VAX-24 for preventing invasive pneumococcal disease and pneumonia in healthy adults.

MRK : 106.98 (-0.40%)
SGEN : 139.03 (-0.32%)
AQST : 0.8799 (-1.13%)
PCVX : 44.44 (-2.01%)
Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults

-- Company Expects to Announce Topline Results from the Phase 1 and Phase 2 Portions of the Proof-of-Concept Study in October or November 2022 -- --...

PCVX : 44.44 (-2.01%)
Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503), (President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Sutro Biopharma, Inc. (NASDAQ: STRO), (CEO:...

STRO : 7.33 (+1.24%)
PCVX : 44.44 (-2.01%)
Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503), (President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Sutro Biopharma, Inc. (NASDAQ: STRO), (CEO:...

STRO : 7.33 (+1.24%)
PCVX : 44.44 (-2.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vaxcyte Inc.is a biopharmaceutical company develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate and complex antigen-based vaccines. Vaxcyte Inc.is based in Foster City, California.

See More

Key Turning Points

3rd Resistance Point 47.48
2nd Resistance Point 46.61
1st Resistance Point 45.52
Last Price 44.44
1st Support Level 43.56
2nd Support Level 42.69
3rd Support Level 41.60

See More

52-Week High 49.31
Last Price 44.44
Fibonacci 61.8% 37.14
Fibonacci 50% 33.38
Fibonacci 38.2% 29.61
52-Week Low 17.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar